A testing apparatus for performing an assay, the testing apparatus comprising: a receptacle (2) containing a reagent, the reagent being reactive to an applied test sample by developing a colour or pattern variation; a portable device (1), e.g. a mobile phone or a laptop, comprising a processor and an image capture device (3), wherein the processor is configured to process data captured by the image capture device and output a test result for the applied test sample.

The present invention provides isolated proteins isolatable from a Pasteurella spp. such as P. multocida. Also provided by the present invention are compositions that include one or more of the proteins, and methods for making and methods for using the proteins.

To provide a method for discriminating a microorganism by selecting and using a marker protein capable of reproducibly and quickly discriminating a bacterial species of the genus Listeria. The method for discriminating a microorganism according to the present invention includes: a step of subjecting a sample containing a microorganism to mass spectrometry to obtain a mass spectrum; a reading step of reading a mass-to-charge ratio m/z of a peak derived from a marker protein from the mass spectrum; and a discrimination step of discriminating which bacterial species of Listeria bacteria the microorganism contained in the sample contains based on the mass-to-charge ratio m/z, in which at least one of 17 ribosomal proteins L3, L4, L23, L2, L24, L6, L18, S5, L15, S13, S11, L10, L21, L13, S9, L31, S16 is used as the marker protein and particularly at least one of 8 ribosomal proteins L24, L6, L18, L15, S9, L31, S16 among the 17 ribosomal proteins is used.

A method of diagnosing the presence or absence of colon polyps by using a machine learning model, which is performed by a diagnostic apparatus, includes: analyzing a mixture of a sample collected from a subject and a gut environment-like composition; extracting a plurality of microbial data based on an analysis result of the mixture; selecting a microbe-related feature to be used for the machine learning model from the plurality of microbial data based on a predetermined feature selection algorithm; training the machine learning model by using the microbe-related feature to predict the presence or absence of colon polyps for each of the microbial data; and diagnosing the presence or absence of colon polyps based on an output value of the machine learning model by inputting, into the trained machine learning model, the microbial data extracted based on the analysis result of the mixture of the sample collected from the subject and the gut environment-like composition, wherein the microbe-related feature includes the content of at least one kind of microbes selected from families belonging to the order Oscillospirales, the order Burkholderiales, the order Saccharimonadales, the order Lactobacillales, the order Bacteroidales, the order Clostridiales, the order Erysipelotrichales, the order Bacteroidales and the order Lachnospirales.

The present disclosure provides methods and compositions for testing blood samples to determine the presence and type of a blood stream infection (BSI). In one embodiment, the composition is a lysis reagent or composition that comprises betaine hydrochloride, spermidine, saponin, and Triton® X-100. The methods include combining the lysis reagent with the blood sample, and at least one centrifuge step to isolate the micro-organisms that cause the BSI. The micro-organisms are kept viable so that diagnostic tests can be run on the blood samples after the various method steps are performed.

Embodiments of the present disclosure relate to chimeric antibodies which specifically bind to Borrelia decorin-binding protein A (DbpA) antigens and compositions or kits comprising such antibodies. The disclosure further relates to use of such antibodies in the detection of Borrelia sp. in samples, e.g., biological samples such as human blood and/or tissues of deer, ticks and other carriers of Borrelia. Embodiments of the disclosure further relate to diagnosis and/or therapy of Lyme disease using the chimeric antibodies and/or compositions containing the chimeric antibodies.

Embodiments of the present technology include a method for testing a blood sample for sepsis. The method may include receiving a blood sample from an individual. The method may also include executing an instruction to analyze the blood sample for sepsis. In addition, the method may include measuring values of a set of characteristics in the blood sample. The set of characteristics being determined prior to measuring the values. The method may further include analyzing the values of the set of characteristics to produce a representation of a suspicion of sepsis. In addition, the method may include displaying the representation. Embodiments also include systems for testing blood sample for sepsis.

In at least one illustrative embodiment, an electromagnetic filter may include a transfer pipe and multiple electromagnetic filter elements positioned in an interior volume of the pipe. Each electromagnetic filter element includes a support comb, a solenoid coupled to the support comb, and multiple magnetic members arranged in a planar array positioned within an opening of the support comb. Each magnetic member may rotate about an end that is coupled to the support comb. The magnetic members may be magnetostrictive sensors and may include a biorecognition element to bind with a target microorganism. A method for fluid filtration includes coupling the electromagnetic filter between a fluid source and a fluid destination, energizing the solenoids of each electromagnetic filter elements, and flowing a fluid media through the transfer pipe of the electromagnetic filter. The fluid media may be liquid food such as fruit juice. Other embodiments are described and claimed.

The present invention relates to a point-of-care assay for detecting and differentiating between viral and bacterial infections, which effectively assist in the rapid differentiation of viral and bacterial infections. More particularly, the invention pertains to an immunoassay that rapidly distinguishes between viral and/or bacterial infections, wherein the viral marker is the interferon induced Mx-B protein and the bacterial markers are CRP/PCT/BPI.

The invention relates to allergic disease, to the development of allergic disease in infants, to determining the likelihood of development of allergic disease in infants and to minimizing the likelihood of development of allergic disease in infants.